Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.
cbdMD, Inc. reports developments in hemp-derived cannabinoid consumer products, including the cbdMD, Paw CBD, Bluebird Botanicals and Herbal Oasis brands.
Company news focuses on CBD product categories, THC-infused social seltzer distribution, clinical and regulatory science initiatives, acquisitions, financial results, liquidity, balance-sheet actions and exchange-listing compliance.
cbdMD (NYSE American: YCBD) announced that its Oasis line of hemp-derived beverages is now available across South Carolina through a new distribution agreement with Morales Beverage Group, a statewide alcohol distributor. The deal places Oasis products on liquor store shelves, including at Frugal MacDoogal.
The rollout covers the full Oasis portfolio and highlights the new zero-proof, spirit-style Mixer, positioned for cocktails and mixed drinks. According to cbdMD, placing Oasis within established liquor retail channels supports its strategy to reach adult consumers in familiar environments and expand hemp-derived beverage accessibility over time.
cbdMD (NYSE American: YCBD), through its Bluebird Botanicals brand, announced an official partnership with Denver Audubon to support bird conservation in Colorado. The collaboration aligns with Bluebird’s Colorado roots and focus on nature, transparency, and environmental stewardship.
Through the “Buy Bluebird, Save Bluebirds” campaign, Bluebird will contribute 1% of profits from its product sales over three summer months to Denver Audubon’s conservation and education initiatives, including the Colorado Bluebird Project. cbdMD is continuing to invest in Bluebird by reinforcing its historic brand identity and customer relationships rather than repositioning the brand.
cbdMD (NYSE American: YCBD) announced completion of a self-affirmed GRAS determination for its proprietary broad spectrum CBD. An independent toxicologist panel concluded daily intake of up to 200 mg CBD is supported as safe for healthy adults, based on cbdMD-sponsored preclinical, clinical, and peer-reviewed studies in humans, animals, and companion animals.
This safety dossier may help guide product development, healthcare use, and consumer confidence.
cbdMD (NYSE American: YCBD) launched Oasis Mixer, a hemp-derived, zero-proof THC spirit under its Herbal Oasis brand. The quad-filtered, oil-free mixer is translucent, designed to avoid cloudiness, and offered in Citrus and Unflavored. Each bottle has 10mg THC per serving, 170mg total, zero calories, sugar, and carbs, plus a resealable child-resistant cap. Initial production was over-subscribed by distributors, with availability in TN, FL, TX, SC and select NC markets, subject to state laws.
cbdMD (NYSE American: YCBD) welcomed the White House request that Congress ensure fair treatment of hemp-derived products under federal law. The Administration supports hemp reform, preservation of access to appropriate full-spectrum CBD, and a responsible federal framework or extended implementation timeline, aligning with cbdMD's focus on compliant, science-backed products.
cbdMD (NYSE American: YCBD) named Wade Brown as Chief Marketing Officer, elevating him to lead marketing and commercial growth across cbdMD, Paw CBD, Oasis, Bluebird Botanicals, and future brands.
According to cbdMD, recent revenue grew 19% year-over-year and 12% sequentially, supported by core brands and Bluebird integration.
cbdMD (NYSE American: YCBD) reported Q2 FY2026 net sales of $5.6 million, up 19% year-over-year and 12% sequentially, driven by core growth and the Bluebird Botanicals acquisition.
Wholesale sales rose 65%, direct-to-consumer 4%. Operating loss was $0.8 million; net loss to common shareholders was $0.88 million. Working capital reached $5.4 million.
The Bluebird integration is progressing, with positive income in March. cbdMD is building a clinical healthcare channel to serve CMS’s new BEI Medicare pathway for eligible hemp-derived CBD products, aiming to leverage emerging bipartisan hemp legislation and cannabis rescheduling.
cbdMD (NYSE American: YCBD) announced it will host a conference call on Thursday, May 14, 2026 at 4:20 p.m. ET to discuss its March 31, 2026 second quarter financial results and business progress.
Investors can join via phone or webcast, with a replay available through May 14, 2027.
Hawkeye Systems (BGH) announced a Board expansion on May 5, 2026, naming Martin Sumichrast as Chairman and adding Sim Farar, Brad Fleisher, and Ralph Olson; former chairman and CEO Corby Marshall remains on the board.
The company said this follows the appointment of President David Wachsman and signals a shift toward a private equity and merchant banking platform focused initially on crypto, blockchain, and cybersecurity, with planned expansion into other financial services and advanced technology verticals.
cbdMD (NYSE: YCBD) launched a clinical healthcare channel to support physician-supervised use of hemp-derived CBD within select Medicare value-based care models, effective April 1, 2026.
CMS activated the Substance Access Beneficiary Engagement Incentive (BEI) to include eligible hemp-derived cannabinoid products in certain models, and cbdMD highlights OECD toxicology data, an IRB-approved randomized clinical trial, GRAS dossiers, and healthcare-grade supply systems to serve providers.